KOCAA
KPTI icon

Knights of Columbus Asset Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,823
Closed -$761K – 326
2021
Q1 		$761K Sell
4,823
-41
-0.8% -$8.64K 0.07% 252
2020
Q4 		$1.13M Sell
4,864
-9
-0.2% -$2.08K 0.12% 242
2020
Q3 		$1.07M Buy
4,873
+760
+18% +$186K 0.13% 233
2020
Q2 		$1.17M Buy
+4,113
New +$1.22M 0.14% 228

Other funds holding KPTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Knights of Columbus Asset Advisors's KPTI Position: Q2 2021 in Review

Knights of Columbus Asset Advisors sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 4,823 shares — an estimated $761K sold.

Knights of Columbus Asset Advisors first reported a position in KPTI in Q2 2020 and held it in 4 quarters. The position peaked at $1.17M in Q2 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • Knights of Columbus Asset Advisors reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 4,823 Karyopharm Therapeutics shares in Q2 2021, an estimated $761K.
  • Knights of Columbus Asset Advisors first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 4 quarters.
  • Knights of Columbus Asset Advisors's Karyopharm Therapeutics position peaked at $1.17M in Q2 2020.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.